Cognex®
Cognex® (tacrine) is the first reversible cholineseterase inhibitor drug approved for improving cognitive symptoms (i.e., memory, attention, reason, language, and the ability to perform simple tasks) associated with Alzheimer\'s disease.
The use of Cognex® has been limited by its liver toxicity and an inconvenient dosing schedule. It has been reported that 50of patients taking Cognex® experienced liver toxicity.
As a result, patients on Cognex® require periodic liver function tests to monitor their liver enzyme level.
Furthermore, Cognex® has a cumbersome dosing schedule. While other cholinesterase inhibitors are required to be taken once or twice a daily, Cognex® has to be administered four times daily on an empty stomach.
Cognex® (tacrine) is the first reversible cholineseterase inhibitor drug approved for improving cognitive symptoms (i.e., memory, attention, reason, language, and the ability to perform simple tasks) associated with Alzheimer\'s disease.
The use of Cognex® has been limited by its liver toxicity and an inconvenient dosing schedule. It has been reported that 50of patients taking Cognex® experienced liver toxicity.
As a result, patients on Cognex® require periodic liver function tests to monitor their liver enzyme level.
Furthermore, Cognex® has a cumbersome dosing schedule. While other cholinesterase inhibitors are required to be taken once or twice a daily, Cognex® has to be administered four times daily on an empty stomach.
